Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Flags Comparative Effectiveness As Priority For Senate Medicare Bill

Executive Summary

Comparative effectiveness research continues to have traction in Congress. The issue has been flagged as a priority item for inclusion in the Senate Finance Committee forthcoming package of Medicare and other health care provisions, according to a top health aide to committee Chairman Max Baucus, D-Mont

You may also be interested in...



More Research, Little Action On Comparative Effectiveness In Medicare Bill

Despite hopes that research on the comparative effectiveness of health services could both improve health care quality and reduce spending, the creation of an expanded federal program remains stuck in the examination phase

More Research, Little Action On Comparative Effectiveness In Medicare Bill

Despite hopes that research on the comparative effectiveness of health services could both improve health care quality and reduce spending, the creation of an expanded federal program remains stuck in the examination phase

Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel